BCL2 and mantle cell lymphoma: Venetoclax, a Bcl-2 inhibitor, has shown single-agent activity in a phase I study in patients with MCL without prior BTKi treatment, and limited data regarding the efficacy of venetoclax post-BTKi therapy [41].